PDL BioPharma Inc., of Incline Village, Nev., said the U.S. Patent and Trademark Office terminated an interference proceeding initiated by UCB Pharma SA, of Brussels, Belgium, involving Crohn's disease drug Cimzia (certolizumab pegol), a tumor necrosis factor blocker.